 |
 |
 |
 |
 |
 |
 |
 |
 |
Achillion Pharmaceuticals, Inc. Achillion (Nasdaq: ACHN) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, small molecule inhibitors targeting infectious disease. Pipeline programs include a first-in-class HCV replicase inhibitor partnered with Gilead and an HCV protease inhibitor. Additional drug candidates target treatment of HIV and bacterial infections. |
 |
Aerovance, Inc. Aerovance, Inc. is focused on the development and commercialization of biologics for respiratory and inflammatory diseases. The company has several clinical development programs in progress around two novel compounds, an IL4/13 receptor antagonist and a serine protease inhibitor. In May 2006 Aerovance secured $60 million in a financing led by Clarus Ventures. |
 |
Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals (Nasdaq:AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir’s products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease. Zenvia™ is Avanir's lead product candidate for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder (IEED). |
 |
CoMentis, Inc. CoMentis, Inc.. is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer’s disease, AMD and cognitive disorders. The company has two fundamental technology platforms: (i) beta-secretase inhibitors for the treatment of Alzheimer’s disease; and (ii) nACh receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders. |
 |
ESBATech AG Privately-held ESBATech AG is a Zurich, Switzerland based drug discovery and development company focused on advancing antibody fragments for therapeutic applications. |
 |
Globus Medical, Inc. Globus Medical, Inc. is focused on the development of products that enable spine surgeons to employ both fusion and non-fusion solutions to promote healing in patients with spinal disorders. Today Globus is one of the fastest growing spinal implant companies in the world and a recognized leader in the development of motion sparing technology. |
 |
Oxford Immunotec, Ltd Oxford Immunotec Ltd develops and sells clinical diagnostic products based on its patented, regulatory approved T-SPOT® technology. T-SPOT is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection. Oxford Immunotec’s first product T-SPOT®.TB, is a revolutionary new blood test for diagnosing Tuberculosis infection, offering unmatched sensitivity. |
 |
Pearl Therapeutics , Inc. Pearl Therapeutics, Inc. is a privately-held company focused on improving the treatment and prevention of widely prevalent respiratory disorders. Pearl has licensed a suite of particle technologies from Nektar Therapeutics, Inc. to rapidly advance their product candidates through development.
|
 |
Pelikan Technologies, Inc. Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's novel technology. |
 |
Proacta, Inc. Proacta is a private, clinical-stage biotechnology company focused on developing a new generation of hypoxia-activated prodrug compounds to treat cancer. These compounds are designed to improve outcomes of current cancer treatment regimens with a broader tumor killing effect. Proacta’s lead compound is selectively activated in hypoxic regions of solid tumors and can diffuse locally within the tumor to kill non-hypoxic cells. In January 2007, Proacta secured a $35 million Series B financing led by Clarus Ventures. |
 |
SARcode, Inc. SARcode is a private, San Francisco based company focused on the development of small molecule LFA-1 inhibitors to treat inflammatory diseases. In December, 2006 SARcode secured $25 million in a financing co-led by Clarus Ventures and Alta Partners. |
 |
Sientra, Inc. Sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market. In April 2007, Sientra secured $85 million in a Series B financing co-led by Clarus Ventures. |
 |
Taligen Therapeutics, Inc. Taligen is a biopharmaceutical company focused on developing inhibitors of the complement system for a variety of therapeutic indications. Clarus co-led the Series B financing of the company in January 2008. |
 |
TyRx Pharma, Inc. |
 |
Variation Biotechnologies, Inc. Variation Biotechnologies Inc. is focused on the development and commercialization of novel peptide-based vaccines for infectious diseases. The company has several preclinical vaccine development programs in progress for seasonal influenza, pandemic influenza, and HIV. In December 2006, Variation secured $36 million in a financing led by Clarus Ventures. |
 |
Zogenix, Inc. Zogenix, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. Zogenix’ initial focus is the late-stage development and commercialization of Intraject® sumatriptan -- a needle-free, single-use, disposable, subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the migraine market. In August, 2006, Zogenix secured $60 million in a financing co-led by Clarus Ventures. |